Skip to main content
. 2016;17(11):4853–4856. doi: 10.22034/APJCP.2016.17.11.4853

Table 1.

Antitumor Activity of Gimatecan in the Treatment of Subcutaneous Liver Cancer Xenograft Model (by tumor volume). TVI (%) refers to the percentage tumor volume inhibition. aThe P value was determined against vehicle control.

Model Treatment TVI(%) P valuea
Huh-1 Vehicle control -- --
Gimatecan (0.8 mg/kg) 62 <0.001
Gimatecan (0.4 mg/kg) 30 0.002
Gimatecan (0.1 mg/kg) 14 0.140
HepG2 Vehicle control -- --
Gimatecan (0.8 mg/kg) 95 <0.001
Gimatecan (0.4 mg/kg) 74 <0.001
Gimatecan (0.1 mg/kg) 24 0.101
HCCLM3 Vehicle control -- --
Gimatecan(0.8 mg/kg) 88 <0.001
Gimatecan(0.4 mg/kg) 68 <0.001
Gimatecan(0.1 mg/kg) 34 0.014
PLC/PRF/5 Vehicle control -- --
Gimatecan(0.8 mg/kg) 71 <0.001
Gimatecan(0.4 mg/kg) 47 <0.001
Gimatecan(0.1 mg/kg) 4 0.718